Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Identification of AAV serotypes for lung gene therapy in human embryonic stem cell-derived lung organoids

Fig. 2

Native EGFP fluorescence in lung bud organoids on day 5 after rAAV transduction. Lung bud organoids (aged d59) were microinjected with 3.5E8 to 1E9 GC of rAAV serotypes expressing EGFP from either the CMV promoter or hCEFI promoter as indicated. Mock injection with buffer served as a negative control. Five days after injection, LBOs were imaged en face for EGFP fluorescence (aj). One representative image from n = 3–4 injected organoids is shown; for serotypes rAAV6.2, rAAV5 and rAAV9, the image is representative of two independent experiments. Scale bar 200 μm. Quantification of EGFP brightness intensity in en face images of transduced or mock-injected LBOs (k). Brightness was determined as the sum of the values of the pixels in the LBO area of the image and was normalised to LBO size and background fluorescence of the mock injected group. Kruskal-Wallis test comparing the mean rank of each group to the mock injected group. (*) P < 0.05; (**) P < 0.005

Back to article page